

## Oryzon continues to advance prosecution of its LSD1 patent portfolio worldwide

### First notice of allowance received from the European Patent Office (EPO) for one of its LSD1 composition-of-matter EP patent applications

**BARCELONA, SPAIN / CAMBRIDGE MA, August 18th 2015.** Oryzon announced today that it has recently received a notice of allowance from the European Patent Office (EPO) for one of its LSD1 composition-of-matter EP patent applications. This is Oryzon's first LSD1 case to be accepted for grant at the EPO.

With this allowance, Oryzon's LSD1 portfolio currently includes 7 patents granted and 3 more allowed in the USA, 1 case allowed at the EPO, 1 allowed in Australia, 2 granted and 1 more allowed in China, 1 granted in Japan, 2 allowed in Israel and 1 allowed in Mexico.

These grants and notices of allowance together with positive opinions from examiners that have been received in further patent applications support Oryzon's expectations to expand its list of granted/allowed LSD1 cases in the following months and certifies that the company continues to advance firmly prosecution of its LSD1 patent portfolio worldwide, which currently comprises 19 patent families and constitute the most extensive IP position worldwide on the LSD1 field.

Oryzon's first clinical asset, a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA, was partnered in a global deal with ROCHE. Under the terms of the agreement, Oryzon received an upfront payment and near-term milestones totaling \$21 million, plus potential development, commercial and sales milestone payments across haematology, cancer and non-malignant indications that could exceed \$500 million, together with tiered royalties on sales which range up to mid-double digits. This licensed asset is covered by 2 out of the 19 Patent families currently owned by Oryzon in the LSD1 field. The company is also active in developing drugs against other Histone demethylases.

#### ABOUT ORYZON

Founded in 2000 in Barcelona, Spain, Oryzon ([www.oryzon.com](http://www.oryzon.com)) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolio in the field. Its LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one to enter clinical trials by the beginning of 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other histone demethylases and histone methyltransferases. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage

development and commercialization. In October 2014, ORYZON announced opening of U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.

For more information

**ATREVIA**

**Ana Melgar**

[amelgar@atrevia.com](mailto:amelgar@atrevia.com)

Tlf. 915640725

Emili Torrell

Business Development Officer

[etorrell@oryzon.com](mailto:etorrell@oryzon.com)